#USA #Boston #Clinical Trials #Lindus Health #Yendou

Lindus Health and Yendou: A Partnership to Revolutionize Clinical Trials

In an exciting development in the life sciences sector, Lindus Health, known as the "anti-CRO," has joined forces with Yendou, an AI-driven platform focused on site engagement and management. This collaboration is set to transform the clinical trial landscape by streamlining site outreach and improving data management, resulting in faster and more efficient trial feasibility assessments.

The Importance of Site Feasibility

Site feasibility plays a critical role in the success of clinical trials. It involves collecting crucial information from clinical sites regarding their expertise, staff qualifications, access to targeted patient populations, and the timeline for contracting. However, traditional approaches taken by many Contract Research Organizations (CROs) are often transactional and outdated. They frequently use disconnected systems, requiring teams to manually resend questionnaires and re-enter data, creating a frustrating experience for both CROs and sites alike.

How the Partnership Works

The collaboration between Lindus Health and Yendou addresses these challenges head-on by offering a centralized solution for site data storage. With Yendou’s advanced platform, Lindus Health can collect comprehensive site demographics through one-time surveys, which are then stored for future trials, making access easier for the entire team. This persistent memory feature allows for automatic reuse of historical responses, significantly reducing redundancy and saving time.

Moreover, this partnership enables Lindus Health to enhance communication with sites by providing individualized outreach and opening visibility into individual site operations. The automation of onboarding processes, including workflows for introductory meetings and NDAs, will improve coordination and relationship-building efforts.

Measurable Impacts and Outcomes

What truly sets Yendou apart is its ability to transform communication metrics into actionable insights. By measuring the speed and quality of site engagement during every interaction, Lindus Health can develop a personalized ranking system based on real performance data. This approach eliminates reliance on generic market benchmarks and allows for tailored engagement strategies. As a result, Lindus Health can predict which sites will activate most quickly and reliably, fostering a system of continuous improvement in trial feasibility.

Early results from this partnership are promising. Teams at Lindus Health have already recorded time savings of over six hours per full-time employee each week, previously devoted to manual tasks. Freed from this burden, the focus can shift towards building stronger connections with sites, such as increasing early input from Principal Investigators (PIs) and creating transparent visibility into trial pipelines.

In just eight weeks post-launch, the collaboration has led to a remarkable increase in trial scope, with 394% more qualified sites and a staggering 15-fold increase in investigators reported. This not only expands Lindus Health's network of sites but also fortifies trust in established relationships.

Comments from Leadership

Meri Beckwith, Co-CEO of Lindus Health, emphasized the significance of this strategy: “When sites feel valued as strategic partners, everything changes—trust deepens, loyalty strengthens, and response times accelerate.” This partnership with Yendou is pivotal in realizing that vision.

A Unified Solution for Clinical Trials

The alliance enhances Lindus Health’s capability to conduct robust, comprehensive clinical trials through a singular, unified platform. By incorporating Yendou's system, Lindus Health is positioned to innovate further in trial execution, leveraging technology and strategic insights to accelerate the delivery of groundbreaking therapies.

In conclusion, the partnership between Lindus Health and Yendou represents a significant advancement in clinical trial management, showcasing the potential of technology to improve efficiency and foster collaborative relationships. Both organizations are committed to making clinical trials faster, more reliable, and ultimately more beneficial for life science pioneers and the patients they serve.